CERT250117C10000
- 1.50
- 0.000.00%
Certara Newsroom
Certara's Solid FY24 Performance and Cautious Outlook Lead to Hold Rating Despite Increased Price Target
BofA Securities Maintains Certara(CERT.US) With Buy Rating, Maintains Target Price $15
BofA Securities Maintains Certara(CERT.US) With Buy Rating, Announces Target Price $15
Certara's Strong Financial Performance and Strategic AI Positioning Drive Positive Outlook
Certara Up Over 10%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk
Certara Shares Are Trading Higher After the Company Provided Q4 and FY24 Revenue and Adjusted EBITDA Guidance.
Certara | 8-K: Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Express News | Certara Inc: Continues to Expect Adj Ebitda for FY24 Between Previously Disclosed Guidance Range of $120 Mln and $124 Mln
Express News | Certara Inc Qtrly Revenue of $99.7 Million
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Certara Sees 2024 Rev $384.4M >CERT
Press Release: Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Express News | Certara Inc : Baird Cuts Target Price to $12 From $13
Is There Now An Opportunity In Certara, Inc. (NASDAQ:CERT)?
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Certara Participates in a Conference Call With Jefferies
Certara | 10-K/A: Annual report (Amendment)
Medical Writing Market Size Indicating $ 9.09 Billion by 2031, Featuring Profiles of Cactus Communications, Certara, Covance, Freyr Solutions, InClin Inc
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Certara Showcases 2024 Research Wins With Over 100 Papers Published